Streetbeat News

Products Services

CLDI

SIGA

Calidi Biotherapeutics shares are trading higher following the announcement of a collaboration with SIGA Technologies to advance Calidi's RTNova virotherapy for lung cancer and metastatic solid tumors.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:59 pm

SPCE

Virgin Galactic Holdings Inc (NYSE:SPCE) shares are trading higher after the company announced the successful completion of its second spaceflight of 2024 and 12th mission to date. The 'Galactic 07' flight carried one researcher and three private astronauts, marking the company's seventh spaceflight carrying microgravity and space-based research. Virgin Galactic is also producing its fourth-generation spaceship, the Delta Class, expected to enter commercial service in 2026.

Portfolio Pulse from Adam Eckert

June 10, 2024 | 12:57 pm

LQR

LQR House Inc. (NASDAQ:LQR) has acquired 1.92 million shares of DRNK Beverage Corp at $2.50 per share, totaling $4.8 million. This strategic investment marks LQR House's entry into the non-alcoholic and ready-to-drink beverage markets.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:48 pm

QCOM

WLDS

Wearable Devices has integrated its technology with Qualcomm's Snapdragon Spaces, addressing key limitations in camera-based hand tracking for augmented and virtual reality applications.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:47 pm

BNRG

Brenmiller Energy has entered the construction phase of Tempo's beverage manufacturing plant, marking a significant milestone in their project timeline.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:46 pm

NEOG

Neogen's Molecular Detection System has been named the primary method for Salmonella and Listeria testing in meat, poultry, and egg products by the USDA Food Safety and Inspection Service (FSIS).

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:46 pm

SLS

SELLAS Life Sciences has completed enrollment and reported positive initial data from its Phase 2a trial of SLS009 in relapsed/refractory acute myeloid leukemia. The trial showed promising response rates and overall survival improvements, particularly in patients with specific genetic mutations.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:41 pm

SLS

SELLAS Life Sciences has completed enrollment and reported positive initial data from its Phase 2a trial of SLS009 in relapsed/refractory acute myeloid leukemia. The trial showed promising overall response rates and median overall survival improvements.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:41 pm

MSFT

PERI

Perion Network Ltd. (NASDAQ:PERI) has lowered its Q2 and FY24 financial guidance due to changes in Microsoft Bing ad pricing and a decline in revenue from standard video and display formats. The company expects significant impacts on its revenue and EBITDA, leading to a 24.4% drop in its stock price.

Portfolio Pulse from Lekha Gupta

June 10, 2024 | 12:39 pm

GILD

RCUS

Arcus Biosciences, in collaboration with Gilead Sciences, has completed patient enrollment for a Phase 3 trial evaluating a domvanalimab-containing regimen for first-line metastatic upper GI cancers. Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper GI adenocarcinomas, potentially making it first-to-market for this patient population.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:38 pm